Although OVV-mNbTIM3 cured 80% of the mice’s tumors, combination therapy with anti-PD-1 or anti-CTLA4 further promoted complete tumor remission in mice, achieving 100% or 90% remission rates respectively. This evidence concerns the gene CTLA4 and neoplasm.